Physician profile
Ewa Gniado
NPI 1003221169
$5,549.51
in general payments reported to CMS, 2019-2025
35 companies · $2,689 in 2025
The $2,689 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.49 · 2023: $835 · 2024: $1,972 · 2025: $2,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,480 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,479.75 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,737.12 | 2023-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $498.98 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $406.88 | 2023-2025 | |
| Lilly USA, LLC | $332.21 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $323.93 | 2023-2025 | Omnipod |
| Mannkind Corporation | $264.76 | 2023-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $188.92 | 2024-2025 | |
| Radius Health, INC. | $151.31 | 2023-2025 | Tymlos |
| Ascendis Pharma Endocrinology INC | $143.04 | 2025 | Yorvipath |
| Neurocrine Biosciences, INC. | $136.65 | 2024-2025 | |
| Alvogen INC | $130.84 | 2024-2025 | Teriparatide |
| Medtronic, INC. | $103.14 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Corcept Therapeutics | $101.54 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $97.62 | 2024-2025 | Recorlev |
| Recordati_rare_diseases_inc. | $91.42 | 2024-2025 | Isturisa, Signifor Lar |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $91.06 | 2024-2025 | |
| Abbott Laboratories | $83.15 | 2022-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $74.78 | 2024-2025 | Xyosted |
| Amphastar Pharmaceuticals, INC. | $56.94 | 2023-2025 | Baqsimi |
| Dexcom, INC. | $55.73 | 2023-2024 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $51.41 | 2025 | |
| Tandem Diabetes Care, INC. | $51.12 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar, INC. | $48.36 | 2023-2024 | |
| Kyowa Kirin, INC. | $45.75 | 2025 | |
| Madrigal Pharmaceuticals | $41.71 | 2024 | Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.27 | 2024-2025 | Jardiance |
| Amryt Pharma Holdings LTD | $35.81 | 2023 | Mycapssa |
| Amneal Pharmaceuticals LLC | $33.39 | 2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $26.93 | 2025 | Strensiq |
| Theracosbio, LLC | $22.00 | 2024 | Brenzavvy |
| Bayer Healthcare Pharmaceuticals INC. | $19.96 | 2023 | |
| Sequel Med Tech, LLC | $19.91 | 2025 | Twiist |
| Chiesi USA, INC. | $15.08 | 2024 | Mycapssa |
| Novartis Pharmaceuticals Corporation | $15.01 | 2024 | |
| Verity Pharmaceuticals INC. | $14.78 | 2025 | Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewa Gniado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.